X0609 4 2026-04-07 1 0000859737 HOLOGIC INC HOLX 0001748821 COHN BENJAMIN JORDAN false 250 CAMPUS DRIVE MARLBOROUGH MA 01752 1 Principal Accounting Officer 0 Common Stock 2026-04-07 4 D 0 17964 D 0 D Non-qualified Stock Option (Right to Buy) 45.61 2026-04-07 4 D 0 10861 D 2029-11-11 Common Stock 10861 0 D Non-qualified Stock Option (Right to Buy) 68.35 2026-04-07 4 D 0 7505 D 2030-11-09 Common Stock 7505 0 D Non-qualified Stock Option (Right to Buy) 71.13 2026-04-07 4 D 0 7132 D 2031-11-08 Common Stock 7132 0 D Non-qualified Stock Option (Right to Buy) 74.35 2026-04-07 4 D 0 3382 D 2032-11-07 Common Stock 3382 0 D Non-qualified Stock Option (Right to Buy) 71.94 2026-04-07 4 D 0 3509 D 2033-11-14 Common Stock 3509 0 D Non-qualified Stock Option (Right to Buy) 79.39 2026-04-07 4 D 0 3505 D 2034-11-11 Common Stock 3505 0 D Performance Stock Units 2026-04-07 4 A 0 5665 A Common Stock 5665 5665 D Performance Stock Units 2026-04-07 4 D 0 5665 D Common Stock 5665 0 D Includes 80 shares of common stock acquired pursuant to Hologic's employee stock purchase plan since the date of the reporting person's most recently filed Form 4. Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and each Company RSU held by the reporting person granted after October 21, 2025 converted into, for each share of Company Common Stock subject to such Company RSU immediately prior to the Effective Time, (i) an unvested award representing the right to receive a cash payment equal to the Cash Consideration, and (ii) an unvested award representing the right to receive cash payments equal to the payments to the holder of one CVR, if any, pursuant to the CVR agreement, in each case, subject to the terms applied to the corresponding Company RSU immediately prior to the Effective Time. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. For Footnote (4), see Remarks below. Each Hologic restricted stock unit represents a contingent right to receive one share of Company Common Stock. Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic. Pursuant to the Merger Agreement, for purposes of determining the number of shares of Company Common Stock subject to each PSU, any applicable performance goals were deemed achieved at the greater of (A) the target level of performance and (B) the actual level of performance measured through the latest practicable date prior to the Effective Time. Pursuant to the Merger Agreement, each outstanding PSU was cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such PSU. (4) Pursuant to the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (a "Company Option") with an exercise price per share less than the Cash Consideration was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (A) the number of shares of Company Common Stock subject to such Company Option, multiplied by (B) the excess of the Cash Consideration over the exercise price per share of the Company Option, and (ii) one CVR with respect to each share. Each outstanding Company Option with an exercise price per share equal to or greater than the Cash Consideration and less than the sum of the Cash Consideration and $3.00 was cancelled and converted into the right to receive one CVR with respect to each share of Company Common Stock subject to such Company Option, payment in respect of which will be net of the excess of the applicable exercise price per share of the Company Option over $76.00. Each outstanding Company Option with an exercise price per share of Company Common Stock equal to or greater than the sum of the Cash Consideration and $3.00 was cancelled for no consideration. /s/ Mark W. Irving, attorney-in-fact for Mr. Cohn 2026-04-09